Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06489041
NA

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.

Official title: Evaluating the Use of Microarray Pharmacogenetic Testing in Patients With Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-07-18

Completion Date

2026-12

Last Updated

2026-02-02

Healthy Volunteers

No

Interventions

GENETIC

Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"

Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.

Locations (1)

Atrium Health Levine Cancer

Charlotte, North Carolina, United States